Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zydus Mounts Challenge To Novartis With Generic Nelarabine Injection

US Rival To Arranon Has Been Granted 180 Days Of CGT Exclusivity

Executive Summary

Zydus Cadila’s single-dose nelarabine injection (250mg/50ml) will enjoy 180 days of competitive generic therapy market exclusivity following approval from the US FDA, as the first approved rival to Novartis’ Arranon brand.

You may also be interested in...



Zydus Knocked Back On Farxiga In US As Brand Continues To Grow

Zydus Cadila has failed to prove to a US court that a US patent expiring in October 2025 that shields AstraZeneca’s Farxiga (dapagliflozin) SGLT2 inhibitor is obvious, keeping the firm’s proposed ANDA product off of the market for now.

Teva Settles With Pfizer Over Xeljanz XR As 2025 Date Looms

Teva has opted against litigating with Pfizer over its controversial Xeljanz XR JAK inhibitor, settling patent infringement proceedings over a US patent scheduled to expire in 2034. Zydus Cadila recently bagged 180 days of exclusivity for a strength of its ANDA product.

Zydus In-Licensees Enoxaparin In US As It Plots $250m Injectables Business

Zydus Cadila has partnered with an Italian manufacturer to launch a generic version of preservative free Lovenox. Days earlier, the Indian firm’s management had discussed its hopes and expectations for its fledgling US injectables business.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel